Home » Topics » Cardiovascular, BioWorld Science

Cardiovascular, BioWorld Science
RSS

Chloride channel blockers as novel therapeutic approach to sickle cell disease and other disorders

May 15, 2000

Medinox and Fuso to collaborate on development of new NO-neutralizing drug

May 12, 2000

Actelion announces results from phase III trial in pulmonary hypertension

May 12, 2000

Endovasc obtains funding to advance preclinical testing of NRA

May 12, 2000

Angiotensin II inhibition reduces early atherogenesis in monkeys

May 8, 2000

Approval of new indications for ACE inhibitor recommended by FDA advisory panel

May 4, 2000

Pfizer's new CETP inhibitors claimed for atherosclerosis and associated conditions

May 4, 2000

Sleep apnea linked to increased risk of hypertension

May 3, 2000

Trial demonstrates superior efficacy of amiodarone in treating atrial fibrillation

May 3, 2000

Benzoylguanidines synthesized at Boehringer Ingelheim as Na+/H+ exchange inhibitors

May 3, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...